HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige's Monistat, Summer's Eve Brands Key Drivers In Consumer Health Focus

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

BC and Goody's OTC acetaminophen formulations perhaps are the firm's most known consumer health brands but they account for 12% of its revenues while its Monistat and Summer's Eve brands drove 27% of its sales in its latest quarter. The feminine hygiene brands' contribution, says a Jefferies analyst , will only grow with the firm selling its household care brands to focus entirely on the consumer health market.

You may also be interested in...



Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

Prestige Brands' Business Is Exclusively OTC Drugs As It Completes House Cleaning

Prestige Brands has $69m deal to divest its household cleaning business, its final non-OTC assets.. The firm will keep its “power core” OTC brands including Monistat, Summer’s Eve and Goody’s as its marketing focus.

Prestige Brands Acquires C.B. Fleet, Boosts Women’s OTC Platform

Prestige Brands makes the deal three weeks after divesting the slower-selling Massengill douche brand and as it makes a top marketing priority of growing sales of its Monistat yeast treatment line.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122716

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel